Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
02:36pm, Wednesday, 26'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen
Insmed to Present at the Cowen and Company 40th Annual Health Care Conference
01:00pm, Wednesday, 26'th Feb 2020
BRIDGEWATER, N.J., Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
H.C. Wainwright Reaffirms Their Buy Rating on Insmed (INSM)
12:13pm, Wednesday, 26'th Feb 2020
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (INSM) today and set a price target of $52.00. The company's shares closed last
Insmed (INSM) Q4 2019 Earnings Call Transcript
03:01am, Wednesday, 26'th Feb 2020
INSM earnings call for the period ending December 31, 2019.
Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call Transcript
09:53pm, Tuesday, 25'th Feb 2020
Insmed Incorporated (NASDAQ:INSM) Q4 2019 Earnings Conference Call February 25, 2020 8:30 AM ET Company Participants Eleanor Barisser - Investor Relations Will
Insmed (INSM) Gets a Buy Rating from Cowen & Co.
09:14pm, Tuesday, 25'th Feb 2020
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed (INSM) today and set a price target of $56.00. The company's shares closed last
Insmed (INSM) Gets a Buy Rating from Cowen & Co.
09:14pm, Tuesday, 25'th Feb 2020
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed (INSM – Research Report) today and set a
BRIEF-Insmed Sees Full-Year 2020 Arikayce Revenue Of $180 Million To $220 Million
05:56pm, Tuesday, 25'th Feb 2020
Insmed Inc:
BRIEF-Insmed Reports Q4 Gaap Loss Per Share of $0.59
05:19pm, Tuesday, 25'th Feb 2020
Insmed Inc:
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
01:55pm, Tuesday, 25'th Feb 2020
Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
01:55pm, Tuesday, 25'th Feb 2020
Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Insmed down 13% premarket on Q4 results
01:48pm, Tuesday, 25'th Feb 2020
Insmed (INSM) Q4 results:Revenues: $45.7M (+366.3%).Net loss: ($53M) (+42.1%); loss/share: ($0.59) (+50.4%); Quick Assets: $487.4M (-1.6%).2020 Guidance: ARIKAYCE revenue: $180M - 220M vs. $225.79M S&
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
01:28pm, Tuesday, 25'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainst
Insmed: 4Q Earnings Snapshot
12:48pm, Tuesday, 25'th Feb 2020
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Tuesday reported a loss of $53 million in its fourth quarter.
On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 59 ce
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
12:30pm, Tuesday, 25'th Feb 2020
BRIDGEWATER, N.J., Feb. 25, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
